Identifying the four shades of acute decompensation of cirrhosis

作者
Carmine Gambino,Salvatore Piano
出处
期刊:United European gastroenterology journal [Wiley]
卷期号:9 (4): 421-422 被引量:6
标识
DOI:10.1002/ueg2.12074
摘要

Liver cirrhosis is traditionally classified into an asymptomatic phase, namely “compensated” cirrhosis, and a symptomatic phase, namely “decompensated” cirrhosis, characterized by the occurrence of complications of cirrhosis (ascites, variceal bleeding, and hepatic encephalopathy), which are associated with poor survival and quality of life.1 Decompensation usually occurs suddenly leading to hospitalization (acute decompensation [AD]). Although the occurrence of AD is well known to mark the transition from compensated to decompensated cirrhosis, recent findings suggest that patients with AD are quite heterogeneous. The CANONIC study clearly identified a specific subgroup of patients with AD characterized by severe systemic inflammation, organ failures, mitochondrial dysfunction, and high short-term mortality (>15% at 28 days).2-4 This distinct syndrome has been called acute on chronic liver failure (ACLF), involves about one-third of patients with AD2 and occurs in about 40% of patients with cirrhosis within 10 years.5 However, ​in clinical practice, patients with AD without ACLF still constitute a heterogeneous group of patients. The PREDICT study recently described three different clinical courses of AD with different pathophysiology and prognosis: stable decompensated cirrhosis (SDC), unstable decompensated cirrhosis (UDC), and pre-ACLF.6 Patients with SDC did not develop ACLF; they neither require readmission nor die during the 3 months after the enrollment. The clinical course of SDC is characterized by a very low 1-year mortality (10%). UDC was characterized by at least one readmission or death in the 3 months after inclusion; the mortality rates for this clinical entity were 21% and 36% at 3 months and 1 year, respectively. By definition, all pre-ACLF patients developed ACLF within 3 months after enrollment and had the highest 3-month (54%) and 1-year (67%) mortality rates. Pre-ACLF was characterized by higher prevalence of bacterial infections and higher degree of inflammation, while UDC was characterized by a higher prevalence of surrogates of severe portal hypertension. In the current issue of the United European Gastroenterology Journal, Balcar et al. evaluated the prevalence and outcomes of these subgroups of AD in a large cohort of hospitalized patients with cirrhosis in a tertiary care center.7 In this study, 210 patients hospitalized for AD without (n = 173) or with ACLF (n = 37, comparator) were included and followed up for a period of 60 months. Most of the patients with AD (58%) had UDC, while 26% were classified as SDC and 16% as pre-ACLF. Noteworthy, the 3-month and 1-year mortality rates were comparable to those observed in the PREDICT study for pre-ACLF patients (43% and 75%, respectively), but SDC and UDC patients had better outcomes (1-year mortality rates, 7% for SDC and 20% for UDC), probably because most of the patients were included at their first episode of AD. Once again in keeping with the PREDICT study, Balcar et al. found that pre-ACLF patients had higher grade of systemic inflammation compared to SDC and UDC patients, as evidenced by higher levels of C-reactive protein, thus supporting the current hypothesis that systemic inflammation plays a pivotal role in determining the clinical courses of patients with AD.8 The study by Balcar et al. had some specific features such as the availability of hepatic venous pressure gradient (HVPG) in a subgroup of patients and long-term follow-up.7 HVPG was not significantly different in the four groups, suggesting that although portal hypertension is necessary for decompensation, inflammation drives the pattern of decompensation.8 Balcar et al. found that 22% and 31% of patients with SDC and UDC, respectively, developed ACLF during long-term follow-up, therefore, suggesting that ACLF may occur even in less-risky patients. Finally, the highest long-term mortality rate was observed in pre-ACLF patients suggesting that these patients need an aggressive treatment and early assessment for liver transplant eligibility. Both PREDICT study and Balcar study classified AD patterns according to subsequent outcomes; however, in clinical practice, it is hard to identify to which pattern the patients with AD belong to. Future studies should address this issue; meanwhile, those with more severe systemic inflammation (e.g., higher C-reactive protein level, bacterial infections) and CLIF-C AD score ≥50 deserve a more aggressive management and an early assessment for liver transplant eligibility. Carmine Gambino and Salvatore Piano have nothing to disclose regarding the content of this manuscript. Salvatore Piano advises Mallinckrodt. The data that support the findings of this study are available on request from the corresponding author.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
隐形小刺猬完成签到,获得积分10
1秒前
漾漾完成签到,获得积分10
1秒前
FashionBoy的应助被DHY采纳,获得10
1秒前
君无双的应助被Code_king采纳,获得10
1秒前
Youdge的应助被aotuxiaodi采纳,获得20
2秒前
顾矜的应助被喜羊羊采纳,获得10
2秒前
Zhangyangyang完成签到 ,获得积分10
2秒前
哈哈喽完成签到,获得积分10
2秒前
春夏完成签到 ,获得积分10
3秒前
冰薇发布了新的文献求助10
4秒前
称心言发布了新的文献求助20
4秒前
4秒前
4秒前
今后的应助被愉快之槐采纳,获得10
4秒前
juzipi完成签到,获得积分10
5秒前
打打的应助被clio采纳,获得10
5秒前
卢珈馨发布了新的文献求助10
5秒前
molihuakai的应助被谨慎觅露采纳,获得10
5秒前
李健的应助被bcc采纳,获得10
5秒前
极限001的应助被多多多加香菜采纳,获得100
5秒前
聪明芹发布了新的文献求助10
5秒前
KarryLiu完成签到,获得积分10
6秒前
辛勤浩轩发布了新的文献求助10
6秒前
6秒前
7秒前
大模型的应助被Temperance采纳,获得10
7秒前
独特十三完成签到,获得积分10
7秒前
田様的应助被Code_king采纳,获得10
7秒前
CipherSage的应助被Code_king采纳,获得10
7秒前
苗条的芒果完成签到,获得积分10
7秒前
隐形曼青的应助被Code_king采纳,获得10
7秒前
orixero的应助被Code_king采纳,获得10
7秒前
小蘑菇的应助被Code_king采纳,获得10
8秒前
丘比特的应助被Code_king采纳,获得10
8秒前
Ava的应助被gyq采纳,获得10
8秒前
8秒前
xiangpica发布了新的文献求助10
9秒前
9秒前
9秒前
ding的应助被坚定的问芙采纳,获得10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176573
求助须知:如何正确求助?哪些是违规求助? 9567927
关于积分的说明 21795369
捐赠科研通 7771232
什么是DOI,文献DOI怎么找? 3432070
关于科研通互助平台的介绍 2556429
邀请新用户注册赠送积分活动 2477707